Developed by |
Supported by |
|
University of Washington https://www.washington.edu/United States The University of Washington is a public research university based in Seattle, Washington, USA. Originally founded in 1861, the institution has an extraordinary track record of scientific inventions & discoveries. Its Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART) program aims to develop safe, stable, scalable and tolerable long-acting ART combinations for the treatment of HIV. |
tenofovir (aka GS 1278 aka PMPA)
MedChemExpress
lamivudine (aka BCH-189)
MedChemExpress
dolutegravir (aka S/GSK1349572)
MedChemExpress
Aqueous drug particle suspension, Based on other organic particles
Subcutaneous
Not provided
Not provided
No delivery device
A novel long-acting TLD drug-combination nano-particulate (DcNP) formulation for subcutaneous injection was prepared with biocompatible lipid excipients. The highly-scalable DcNP technology enables drugs with disparate physiochemical properties to be formulated into products that remain stable in aqueous suspension. First, TLD was dissolved with lipid-excipients in hydrated-alcohol, followed by a controlled solvent-removal process to create the TLD-DcNP powder. Next, the TLD-DcNP particle-size was reduced (60-80 nm) resulting in a stable-injectable TLD product suitable for subcutaneous dosing.
Rotary evaporator (rotavap). High pressure homogeniser (e.g. Emulsiflex-c5; Avestin Inc., Canada). Spray-dryer (e.g. 4M8Trix Unit; ProCepT, Belgium).
TLD-in-DcNP injectable suspension was prepared by dissolving 40.27 mmol DSPC, 5.97mmol HCl, 5.66 mmol DTG and 4.49mmol mPEG2000-DSPE in 472 ml ethanol at 70°C. Following dissolution, 28 ml of 200 mM NaHCO3 buffer containing 5.85 mmol TFV and 5.85 mmol 3TC was added. The solution was then spray-dried under controlled-solvent-removal process to generate the TLD-in-DcNP powder. The powder in 0.45% w/v NaCl–20 mM NaHCO3 buffer suspension was held at 75°C and homogenised to achieve stable particles (50–70 nm). The suspension was cooled to 25°C and stored at 4°C.
Particle size determined by photon correlation spectroscopy using a NICOMP 380 ZLS (Particle Sizing Systems, Santa Barbara, CA). Osmolality (Vapro 5520 osmometer; Wescor, Logan, UT) and pH (Hydrion paper). Drug quantification via LC-MS/MS using acetonitrile precipitation.
Lipid excipients: DSPC and DSPE-mPEG2000
Not provided
Not provided
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Glecaprevir/Pibrentasvir use in HCV (without IFN or RBV) - treatment regimen
Expiry date: 2038-02-09 The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. |
CA2994496 | Use | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | United States of America | |
Filed | Canada | |
Not in force | China, Brazil, Mexico, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Moldova, Republic of, Morocco, Tunisia | Australia, Japan, United States of America, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Solid composition comprising dispersed atovaquone nanoparticles
Expiry date: 2037-06-15 A solid composition comprising nanoparticles of atovaquone dispersed within one or more carrier materials, wherein the atovaquone is present in an amount of at least 10 wt%. Also described is an intramuscularly- or subcutaneously-injectable formulation of nanoparticles of atovaquone |
WO2017216564 | Composition | The Johns Hopkins University, The University of Liverpool | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | China, India, Sierra Leone, Eswatini, Liberia, Namibia, Sao Tome and Principe, Mozambique, Zambia, Zimbabwe, Tanzania, United Republic of, Malawi, Ghana, Rwanda, Sudan, Botswana, Lesotho, Kenya, Gambia (the) | Australia, Canada |
Filed | Brazil, Albania, Serbia, Türkiye, North Macedonia, South Africa | Liechtenstein, Italy, Norway, Malta, Denmark, Belgium, United Kingdom, Greece, Netherlands, Hungary, Croatia, Switzerland, Spain, San Marino, Slovenia, Austria, Romania, Iceland, Cyprus, Finland, France, Bulgaria, Slovakia, Poland, Latvia, Ireland, Estonia, Germany, Luxembourg, Portugal, Czechia, Lithuania, Monaco, Sweden, Japan, United States of America |
Not in force | World Intellectual Property Organization (WIPO), Morocco, Bosnia and Herzegovina, Montenegro, Moldova, Republic of, Uganda | World Intellectual Property Organization (WIPO), Chile, United States of America |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Glecaprevir/Pibrentasvir solid compositions II
Expiry date: 2036-07-18 The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion. |
WO2017015211 | Composition | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | China, South Africa | Australia, Canada, Japan, Korea, Republic of, Israel, Panama |
Filed | Costa Rica, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Egypt, Viet Nam, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Ecuador, Guatemala, Mongolia, Thailand | Russian Federation, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia, New Zealand, Singapore, Hong Kong |
Not in force | World Intellectual Property Organization (WIPO), Brazil, Colombia, Philippines, Peru, Dominican Republic, Indonesia, India, Mexico, Moldova, Republic of, Malaysia, Ukraine | United States of America, World Intellectual Property Organization (WIPO), Chile, Russian Federation |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Glecaprevir/Pibrentasvir solid compositions I
Expiry date: 2036-06-24 The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion. |
WO2016210273 | Composition | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | Mexico, Indonesia, South Africa, Mongolia, Malaysia, Colombia | Australia, Israel, Japan, Korea, Republic of, United States of America, Panama |
Filed | Brazil, Costa Rica, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Türkiye, Egypt, India, Ecuador, Guatemala, Thailand, Albania, North Macedonia, Serbia, Bosnia and Herzegovina, Montenegro | Canada, United States of America, Belgium, Russian Federation, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, New Zealand, Singapore, Hong Kong, Iceland, Norway, Poland, Romania, San Marino, Croatia, Latvia, Lithuania, Malta, Slovenia |
Not in force | World Intellectual Property Organization (WIPO), Philippines, China, Dominican Republic, Peru, Viet Nam, Ukraine | Japan, United States of America, World Intellectual Property Organization (WIPO), Chile, Russian Federation |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Glecaprevir crystal forms
Expiry date: 2035-06-05 The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of Figures 1-4. |
WO2015188045 | Polymorphs | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | Mexico | United States of America, Australia |
Filed | Türkiye, North Macedonia, Albania, Serbia, China | Canada, Japan, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia |
Not in force | World Intellectual Property Organization (WIPO), Bosnia and Herzegovina, Montenegro, Morocco | Australia, Japan, World Intellectual Property Organization (WIPO) |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Pibrentasvir crystal forms
Expiry date: 2035-05-08 The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in one of Figures 1-10. |
WO2015171993 | Polymorphs | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | Mexico | Australia, Japan, United States of America |
Filed | China, Albania, Serbia, Türkiye, North Macedonia | Canada, Liechtenstein, Italy, Norway, Malta, Denmark, Belgium, United Kingdom, Greece, Netherlands, Hungary, Croatia, Switzerland, Spain, San Marino, Slovenia, Austria, Romania, Iceland, Cyprus, Finland, France, Bulgaria, Slovakia, Poland, Latvia, Ireland, Estonia, Germany, Luxembourg, Portugal, Czechia, Lithuania, Monaco, Sweden, United States of America |
Not in force | World Intellectual Property Organization (WIPO), China, Morocco, Albania, Serbia, Bosnia and Herzegovina, Montenegro, Türkiye, North Macedonia, Mexico | World Intellectual Property Organization (WIPO), Australia, Liechtenstein, Italy, Norway, Malta, Denmark, Belgium, United Kingdom, Greece, Netherlands, Hungary, Croatia, Switzerland, Spain, San Marino, Slovenia, Austria, Romania, Iceland, Cyprus, Finland, France, Bulgaria, Slovakia, Poland, Latvia, Ireland, Estonia, Germany, Luxembourg, Portugal, Czechia, Lithuania, Monaco, Sweden, Japan |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Glecaprevir/Pibrentasvir use in HCV (without IFN or RBV) II
Expiry date: 2035-04-01 The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. |
WO2015153793 | Use | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | Mexico | Australia, Japan, United States of America |
Filed | China, Albania, North Macedonia, Serbia, Türkiye | Canada, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Finland, Hungary, Iceland, Ireland, Norway, Poland, Portugal, Romania, San Marino, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Latvia, Lithuania, Malta, Monaco, Slovakia, Slovenia, Spain |
Not in force | World Intellectual Property Organization (WIPO), China, Bosnia and Herzegovina, Montenegro, Brazil | Australia, Japan, United States of America, World Intellectual Property Organization (WIPO) |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Glecaprevir/Pibrentasvir and RBV use in HCV (without IFN) II
Expiry date: 2035-04-01 The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. |
WO2015153792 | Use | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | ||
Filed | Taiwan, Province of China | |
Not in force | World Intellectual Property Organization (WIPO), China, Mexico, Albania, North Macedonia, Serbia, Türkiye, Bosnia and Herzegovina, Montenegro | Australia, Canada, Japan, United States of America, World Intellectual Property Organization (WIPO), Belgium, Germany, France, Finland, Greece, Hungary, Iceland, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Austria, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Monaco, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Glecaprevir/Pibrentasvir use in HCV (without IFN or RBV)
Expiry date: 2034-03-14 The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. |
WO2014152514 | Use | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | Brazil, China, Mexico, Serbia, South Africa, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Türkiye, North Macedonia, Albania | Canada, Australia, Cyprus, Denmark, Spain, Croatia, Israel, Japan, Korea, Republic of, New Zealand, Poland, Portugal, Slovenia, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, Russian Federation, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Iceland, Malta, Norway, San Marino, Romania, Latvia, Lithuania |
Filed | Serbia, Türkiye, North Macedonia, Albania | Cyprus, Denmark, Spain, Hong Kong, Croatia, Korea, Republic of, Poland, Portugal, Singapore, Slovenia, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Iceland, Malta, Norway, San Marino, Romania, Latvia, Lithuania |
Not in force | World Intellectual Property Organization (WIPO), China, Mexico, Serbia, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro | Cyprus, Denmark, Spain, Croatia, Japan, Poland, Portugal, Slovenia, Taiwan, Province of China, United States of America, World Intellectual Property Organization (WIPO), Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, Russian Federation, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Iceland, Malta, Norway, San Marino, Romania, Latvia, Lithuania |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Glecaprevir/Pibrentasvir and RBV use in HCV (without IFN)
Expiry date: 2034-03-14 The present invention features interferon -free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 and (b) Compound 2 or a pharmaceutically acceptable salt thereof as disclosed in the description. |
WO2014152635 | Use | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | Serbia, South Africa | Israel, Korea, Republic of |
Filed | Canada, Denmark, Spain, Hong Kong, Croatia, Israel, Poland, Portugal, Singapore, Slovenia, Taiwan, Province of China, Norway, Cyprus | |
Not in force | World Intellectual Property Organization (WIPO), Brazil, China, Mexico, Serbia, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro | Australia, Denmark, Spain, Hong Kong, Croatia, Japan, New Zealand, Poland, Portugal, Slovenia, Taiwan, Province of China, United States of America, World Intellectual Property Organization (WIPO), Russian Federation, Norway, Cyprus, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Iceland, Malta, San Marino, Romania, Latvia, Lithuania |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Pibrentasvir use in HCV
Expiry date: 2033-09-17 Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection. |
WO2014047039 | Use | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | Brazil, Mexico, South Africa, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia | Australia, Japan, New Zealand, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia |
Filed | Mexico, Türkiye, North Macedonia, Albania, Serbia | Canada, Hong Kong, Singapore, Taiwan, Province of China, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia |
Not in force | World Intellectual Property Organization (WIPO), China, Bosnia and Herzegovina, Montenegro | Japan, United States of America, World Intellectual Property Organization (WIPO), Russian Federation |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Carrier liquids and methods of producing such liquids
Expiry date: 2032-08-20 The invention provides a method for the preparation of a carrier liquid which comprises the steps of: (I) preparing a single phase solution comprising: (a) a solvent or a mixture of miscible solvents, (b) a liquid carrier material, which is soluble in solvent (a), and (c) a dopant material which is also soluble in solvent (a); (II) cooling (preferably freezing) the single phase solution produced in step (I) to a temperature at which at least both the solvent (a) and carrier material (b) become solid; and (III) removing solid solvent (a) from the cooled (frozen) single phase solution in vapour form, such that the remaining cooled (frozen) carrier material (b) and dopant material (c) are returned to ambient temperature thus providing a product of liquid carrier material (b) having dopant material (c) dispersed therein. |
WO2013030535 | Process | IOTA NANOSOLUTIONS LIMITED | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | India | United Kingdom, Hungary, France, Ireland, Germany, United States of America |
Filed | ||
Not in force | World Intellectual Property Organization (WIPO), Albania, Serbia, Bosnia and Herzegovina, Montenegro, Türkiye, North Macedonia | World Intellectual Property Organization (WIPO), Liechtenstein, Italy, Norway, Malta, Denmark, Belgium, United Kingdom, Greece, Netherlands, Croatia, Switzerland, Spain, San Marino, Slovenia, Austria, Romania, Iceland, Cyprus, Finland, Bulgaria, Slovakia, Poland, Latvia, Estonia, Luxembourg, Portugal, Czechia, Lithuania, Monaco, Sweden |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Pibrentasvir compound II
Expiry date: 2032-02-24 Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. |
WO2012116257 | Compound | Abbvie Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | China, Mexico | Taiwan, Province of China, Spain, Germany, France, United Kingdom, Italy |
Filed | Spain | |
Not in force | World Intellectual Property Organization (WIPO), Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia | Canada, Japan, United States of America, World Intellectual Property Organization (WIPO), Belgium, Luxembourg, Netherlands, Switzerland, Sweden, Austria, Liechtenstein, Greece, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Slovenia |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Pibrentasvir compound
Expiry date: 2031-10-12 Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. |
WO2012051361 | Compound | Abbott Laboratories | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | Colombia, Argentina, China, Dominican Republic, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Moldova, Republic of, Ecuador, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Mexico, Peru, Ukraine, Bolivia (Plurinational State of), Indonesia, Malaysia, Philippines, Viet Nam, South Africa, Brazil | United States of America, Australia, Chile, Japan, Korea, Republic of, New Zealand, Singapore, Taiwan, Province of China, Uruguay, Denmark, Spain, Portugal, Slovenia, Canada, Israel, Hong Kong, Russian Federation, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, Croatia, Romania, Latvia, Lithuania, Panama |
Filed | Costa Rica, Ecuador, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, India, Bolivia (Plurinational State of), Mongolia, Pakistan, Paraguay, Thailand, Venezuela (Bolivarian Republic of), Guatemala | United States of America, Denmark, Spain, Portugal, Slovenia, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates |
Not in force | World Intellectual Property Organization (WIPO), Costa Rica, Argentina, China, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Moldova, Republic of, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Mexico, Peru, Egypt, Viet Nam | World Intellectual Property Organization (WIPO), Chile, New Zealand, Uruguay, Denmark, Spain, Portugal, Slovenia, Canada, Russian Federation, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Cyprus, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, San Marino, Croatia, Romania, Latvia, Lithuania |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Glecaprevir compound
Expiry date: 2031-09-20 The present invention discloses compounds of Formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. |
WO2012040167 | Compound | Enanta Pharmaceuticals, Inc | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | Argentina, Brazil, China, Colombia, Costa Rica, Dominican Republic, Turkmenistan, Belarus, Tajikistan, Kazakhstan, Azerbaijan, Kyrgyzstan, Armenia, Moldova, Republic of, Ecuador, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Guatemala, Mexico, Peru, South Africa, India, Bolivia (Plurinational State of), Mongolia, Philippines, Malaysia, Pakistan, Indonesia, Ukraine | Canada, Australia, Cyprus, Denmark, Spain, Hong Kong, Croatia, Israel, Japan, Korea, Republic of, New Zealand, Portugal, Singapore, Slovenia, San Marino, United States of America, Chile, Russian Federation, Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, Romania, Latvia, Lithuania, Uruguay, Panama, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates, Macao |
Filed | Argentina, India, Paraguay, Viet Nam, Venezuela (Bolivarian Republic of), Thailand | Cyprus, Denmark, Spain, Croatia, Portugal, Slovenia, San Marino, Taiwan, Province of China, Luxembourg, Netherlands, Hungary, Poland, Norway, Lithuania, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates |
Not in force | World Intellectual Property Organization (WIPO), Colombia, Costa Rica, Dominican Republic, Ecuador, Türkiye, North Macedonia, Albania, Bosnia and Herzegovina, Montenegro, Serbia, Guatemala, Egypt, Malaysia, Indonesia | Australia, Cyprus, Denmark, Spain, Croatia, Japan, Korea, Republic of, Portugal, Slovenia, San Marino, United States of America, World Intellectual Property Organization (WIPO), Belgium, Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Monaco, Ireland, Finland, Bulgaria, Czechia, Estonia, Slovakia, Hungary, Poland, Iceland, Malta, Norway, Romania, Latvia, Lithuania, Uruguay, Bahrain, Kuwait, Qatar, Saudi Arabia, Oman, United Arab Emirates |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Nanodispersions of anti-viral drugs
Expiry date: 2031-04-08 The invention provides a composition and an antiviral drug preparation, each comprising at least one water-insoluble antiviral drug and at least one water-soluble carrier material, wherein the water-insoluble antiviral drug is dispersed through the water-soluble carrier material in nano-disperse form. The present invention further provides processes for preparing the compositions and drug preparations, and also aqueous nano-dispersions obtained by combining water and the compositions. |
WO2011128623 | Composition, Process | Duncalf, David John, Foster, Alison Jayne, Iota Nanosolutions Limited, Long, James, Rannard, Steven Paul, Wang, Dong | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | India | Liechtenstein, Belgium, United Kingdom, Switzerland, Cyprus, France, Ireland, Germany, Luxembourg, Monaco, Israel, United States of America |
Filed | ||
Not in force | World Intellectual Property Organization (WIPO), China, Albania, Serbia, Bosnia and Herzegovina, Montenegro, Türkiye, North Macedonia | World Intellectual Property Organization (WIPO), Canada, Italy, Norway, Malta, Denmark, United Kingdom, Greece, Netherlands, Hungary, Croatia, Spain, San Marino, Slovenia, Austria, Romania, Iceland, Finland, Bulgaria, Slovakia, Poland, Latvia, Estonia, Portugal, Czechia, Lithuania, Sweden, Japan |
Patent description | Representative patent | Categories | Patent holder | Licence with MPP | Patent source |
---|---|---|---|---|---|
Anti-parasitic nano-dispersed compositions
Expiry date: 2027-06-29 The present invention relates to nanodisperse antiparasitcs and provides a composition comprising at least one water insoluble anti-parasitic drug and a water-soluble carrier material, wherein the water-insoluble anti-parasitic drug (preferably an Artemisinin-type drug or a quinine type drug) is dispersed through the carrier material in nano-disperse form having a peak diameter of the nano-disperse form below 1000nm |
WO2008006713 | Composition | Duncalf, David, John, Essa, Asha, Hassan, Foster, Alison, Jayne, Long, James, Rannard, Steven, Paul, Unilever N.V, Unilever Plc, Wang, Dong | Yes |
Patent status/countries | Low, Low- middle and upper-middle | High income |
---|---|---|
Granted | South Africa, Congo, Mauritania, Guinea-Bissau, Niger, Senegal, Cameroon, Mali, Togo, Burkina Faso, Benin, Côte d'Ivoire, Central African Republic, Guinea, Gabon, Equatorial Guinea, Chad | Canada, Liechtenstein, Italy, Belgium, United Kingdom, Netherlands, Hungary, Croatia, Switzerland, Spain, Austria, France, Ireland, Germany, Sweden, United States of America |
Filed | ||
Not in force | World Intellectual Property Organization (WIPO), Argentina, Brazil, China, Albania, Serbia, Bosnia and Herzegovina, Türkiye, North Macedonia, Mexico, South Africa, India, Sierra Leone, Eswatini, Namibia, Mozambique, Uganda, Zambia, Zimbabwe, Tanzania, United Republic of, Malawi, Ghana, Sudan, Botswana, Lesotho, Kenya, Gambia (the), Indonesia | World Intellectual Property Organization (WIPO), Australia, Canada, Chile, Liechtenstein, Italy, Malta, Denmark, Belgium, United Kingdom, Greece, Netherlands, Hungary, Croatia, Switzerland, Spain, Slovenia, Austria, Romania, Iceland, Cyprus, Finland, France, Bulgaria, Slovakia, Poland, Latvia, Ireland, Estonia, Germany, Luxembourg, Portugal, Czechia, Lithuania, Monaco, Sweden, Japan, United States of America, Israel |
Perazzolo S, Stephen ZR, Eguchi M, Xu X, Delle Fratte R, Collier AC, Melvin AJ, Ho RJY. A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable. AIDS. 2023 Nov 15;37(14):2131-2136. DOI: 10.1097/QAD.0000000000003706. Epub 2023 Aug 24. PMID: 37650755; PMCID: PMC10959254.
Objective: To develop an injectable dosage form of the daily oral HIV drugs, tenofovir (T), lamivudine (L), and dolutegravir (D), creating a single, complete, all-in-one TLD 3-drug-combination that demonstrates long-acting pharmacokinetics.
Design: Using drug-combination-nanoparticle (DcNP) technology to stabilize multiple HIV drugs, the 3-HIV drugs TLD, with disparate physical-chemical properties, are stabilized and assembled with lipid-excipients to form TLD-in-DcNP . TLD-in-DcNP is verified to be stable and suitable for subcutaneous administration. To characterize the plasma time-courses and PBMC concentrations for all 3 drugs, single subcutaneous injections of TLD-in-DcNP were given to nonhuman primates (NHP, M. nemestrina ).
Results: Following single-dose TLD-in-DcNP , all drugs exhibited long-acting profiles in NHP plasma with levels that persisted for 4 weeks above predicted viral-effective concentrations for TLD in combination. Times-to-peak were within 24 hr in all NHP for all drugs. Compared to a free-soluble TLD, TLD-in-DcNP provided exposure enhancement and extended duration 7.0-, 2.1-, and 20-fold as AUC boost and 10-, 8.3-, and 5.9-fold as half-life extension. Additionally, DcNP may provide more drug exposure in cells than plasma with PBMC-to-plasma drug ratios exceeding one, suggesting cell-targeted drug-combination delivery.
Conclusions: This study confirms that TLD with disparate properties can be made stable by DcNP to enable TLD concentrations of 4 weeks in NHP. Study results highlighted the potential of TLD-in-DcNP as a convenient all-in-one, complete HIV long-acting product for clinical development.
|
Collaborate for developmentConsider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology Not provided |
|
Share technical information for match-making assessmentProvide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit Not provided |
|
Work with MPP to expand access in LMICsIn the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing Not provided |
Not provided